nach oben

memo - Magazine of European Medical Oncology

Tipp

Fertility preservation in women with endometrial cancer

verfasst von: Helena Bralo, MD, Maria Roethlisberger, MD, Assoc. Prof. Kazem Nouri, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Summary

Fertility preservation should only be offered to patients with endometrial cancer stage Ia grade 1 (G1), who present without myometrial invasion or where the cancer has invaded less than 50% of the myometrium, with no evidence of pathological lymph nodes or no evidence of synchronous or metachronous ovarian tumor. It is estimated that about 22% will achieve successful pregnancy.

Vorheriger Artikel Future perspectives of fertility preservation in women

Nächster Artikel Patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in colorectal cancer

American Cancer Society. Detailed guide: endometrial cancer: what are the risk factors for endometrial cancer? American Cancer Society, Atlanta, GA. 2005. http://www.cancer.org/cancer/endometrialcancer/detailedguide/endometrial-uterine-cancerrisk-factors. Accessed 14.04.2020

https://www.krebsdaten.de/Krebs/DE/Content/Krebsarten/Gebaermutterkoerperkrebs/gebaermutterkoerperkrebs.html. Accessed 14.09.2020

American Cancer Society. Cancer facts and figures 2014. American Cancer Society, Atlanta. 2014. http://www.cancer.org/acs/groups/content/research/documents/webcontent/acspc-042151.pdf. Accessed 14.09.2020

Guillon S, Popescu N, Phelippeau J, Koskas M. A systematic review and meta-analysis, of prognostic factors for remission in fertility sparingmanagement of endometrialatypical hyperplasia and adenocarcinoma. Int J Gynecol Obstet. 2019; https://doi.org/10.1002/ijgo.12882. CrossRef

Wang Y, et al. Impact of treatment duration in fertility-preserving management of endometrial cancer or atypical endometrial hyperplasia. Int J Gynecol Cancer. 2019;29:699–704. https://doi.org/10.1136/ijgc-2018-000081. CrossRefPubMed

Gallup DG, Stock RJ. Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet Gynecol. 1984;64:417–20. PubMed

Soliman PT, Oh JC, Schmeler KM, et al. Risk factors for young premenopausal women with endometrial cancer. Obstet Gynecol. 2005;105:575–80. CrossRef

Haoula Z, Salman M, Atiomo W. Evaluating the association between endometrial cancer and polycystic ovary syndrome. Hum Reprod. 2012;27:1327–31. CrossRef

Tran BN, Connell PP, Waggoner S, et al. Characteristics and outcome of endometrial carcinoma patients age 45 years and younger. Am J Clin Oncol. 2000;23:476–80. CrossRef

10.

Montz FJ, Bristow RE, Bovicelli A, et al. Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol. 2002;186:651–7. CrossRef

11.

Duska LR, Garrett A, Rueda BR. Endometrial cancer in women 40 years old or younger. Gynecol Oncol. 2001;83:388–93. CrossRef

12.

Huang SY, Jung SM, Ng KK, et al. Ovarian metastasis in a nulliparous woman with endometrial adenocarcinoma failing conservative hormonal treatment. Gynecol Oncol. 2005;97:652–5. CrossRef

13.

National Institute for Health and Clinical Excellence CG44. Heavy menstrual bleeding. 2007.

14.

American College of Obstetricians and Gynecologists. Practice bulletin. Diagnosis of abnormal uterine bleeding in reproductive aged women. Obstet Gynecol. 2012;128:1–11.

15.

Pennant ME, Mehta R, Moody P, Hackett G, Prentice A, Sharp SJ, et al. Premenopausal abnormal uterine bleeding and risk of endometrial cancer. BJOG. 2017;124:404–11. CrossRef

16.

Obermair A, Baxter E, Brennan DJ, et al. Fertility-sparing treatment in early endometrial cancer: current state and future strategies. Obstet Gynecol Sci. 2020;63(4):417–31. https://doi.org/10.5468/ogs.19169. CrossRefPubMedPubMedCentral

17.

Walsh C, Holschneider C, Hoang Y. Coexisting ovarian malignancy in young women with endometrial cancer. Obstet Gynecol. 2005;106:693–9. CrossRef

18.

Morice P, Fourchotte V, Sideris L. A need for laparoscopic evaluation of patients with endometrial carcinoma selected for conservative treatment. Gynecol Oncol. 2005;96:245–8. CrossRef

19.

Zarbo G, Caruso G, Caruso S, Mangano U, Zarbo R. Endometrial cancer: preoperative evaluation of myometrial infiltration magnetic resonance imaging versus transvaginal ultrasonography. Eur J Gynaecol Oncol. 2000;21(1):95–7. PMID: 10726632. PubMed

20.

Nouri K, Reinthaller A. Fertilitätserhalt bei prämenopausalen Frauen mit # Endometriumkarzinom im frühen, niedriggradigen Stadium. Speculum. 2015;33(1):12–6.

21.

Cosgrove CM, Cohn DE, Hampel H, et al. Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival. Gynecol Oncol. 2017;146:588–95. CrossRef

22.

Cohn DE, Frankel WL, Resnick KE, et al. Improved survival with an intact DNA mismatch repair system in endometrial cancer. Obstet Gynecol. 2006;108:1208–15. CrossRef

23.

Wei J, Zhang W, Feng L, Gao W. Comparison of fertility-sparing treatments in patients with early endometrial cancer and atypical complex hyperplasia: a meta-analysis and systematic review. Medicine (Baltimore). 2017;96:e8034. CrossRef

24.

Son J, Carr C, Yao M, et al. Endometrial cancer in young women: prognostic factors and treatment outcomes in women aged ≤40 years. Int J Gynecol Cancer. 2020;30:631–9. CrossRef

25.

Harrison RF, He W, Fu S, et al. National patterns of care and fertility outcomes for reproductive-aged women with endometrial cancer oratypical hyperplasia. Am J Obstet Gynecol. 2019;221:474.e1–11.

26.

Mazzon I, Corrado G, Masciullo V, et al. Conservative surgical management of stage IA endometrial carcinoma for fertility preservation. Fertil Steril. 2010;93:1286–9. CrossRef

27.

Ichinose M, Fujimoto A, Osuga Y, et al. The influence of infertility treatment on the prognosis of endometrial cancer and atypical complex endometrial hyperplasia. Int J Gynecol Cancer. 2013;23(2):288–93. https://doi.org/10.1097/IGC.0b013e31827c18a1. CrossRefPubMed

28.

Gallos ID, Yap J, Rajkhowa M, et al. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol. 2012;207:266.e1–266.e12. CrossRef

29.

Fan Z, Li H, Hu R, Liu Y, Liu X, Gu L. Fertility-Preserving Treatment in Young Women With Grade 1 Presumed Stage IA Endometrial Adenocarcinoma: A Meta-Analysis. Int J Gynecol Cancer. 2018;28(2):385–393. https://doi.org/10.1097/IGC.0000000000001164. PMID: 29266019. CrossRefPubMed

30.

Shih KK, Garg K, Levine DA, et al. Clinicopathologic significance of DNA mismatch repair protein defects and endometrial cancer in women 40 years of age and younger. Gynecol Oncol. 2011;123:88–94. CrossRef

Titel: Fertility preservation in women with endometrial cancer
verfasst von: Helena Bralo, MD
Maria Roethlisberger, MD
Assoc. Prof. Kazem Nouri, MD
Publikationsdatum: 29.10.2020
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 4/2020
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-020-00661-6

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Fertility preservation in women with endometrial cancer

Summary

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2020

Patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in colorectal cancer

Position statement of the Austrian Society for Hematology and Medical Oncology on the use of molecular diagnostics in solid tumors

Cytoreductive surgery and HIPEC in colorectal cancer—did we get hold of the wrong end of the stick?

Molecular profiling—ready for clinical routine

Fertility preservation

Homologous recombination deficiency: New biomarkers in innovative treatments